FDA Approved: ZANTAC 360 — Supplemental Application (Chattem, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ZANTAC 360 (famotidine) submitted by Chattem, Inc., under ANDA206531.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Erosive Esophagitis
• Gastric Ulcer
• Gastroesophageal Reflux Disease
• Peptic Ulcer Disease

Drugs mentioned

• ZANTAC 360 (Famotidine)

Snippet

SUPPL AP for ZANTAC 360 (FAMOTIDINE)